01—Abstract
Summary
Summary of the 10-K filed February 27, 2012. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. (CRL) reported 2011 net sales from continuing operations of $1,142.6 milliona, up 0.8% from $1,133.4 million in 2010, with growth driven mainly by the Research Models and Services (RMS) segment, partially offset by lower Preclinical Services (PCS) sales.
Operating income was $174.3 millionb in 2011 versus an operating loss of $298.5 million in 2010, which included a $305.0 million goodwill impairment, $91.4 million in asset impairments and a $30.0 million termination fee. Net income attributable to common shareowners was $109.6 million, or $2.14 per diluted share, compared with a net loss of $336.7 million in 2010. Gross margin rose to 35.2% of net sales from 33.9%, reflecting cost-savings actions and higher RMS sales.
The company describes its business as a provider of solutions that accelerate early-stage drug discovery and development, organized into two segments: RMS (61.7% of 2011 net sales) and PCS (38.3%). Management continued four key initiatives: improving operating margin, improving free cash flow, disciplined investment in growth businesses, and returning value to shareholders. During 2011 the company repurchased 8.4 million shares for approximately $300 millionc, and weighted average shares outstanding fell to 51.3 million from 62.6 million.
Cash and cash equivalents declined to $68.9 milliond from $179.2 million, and total debt was $739 million at December 31, 2011. The filing also notes that PCS backlog was $202.5 million at December 31, 2011, compared with $219.9 million a year earlier, and that management describes market conditions as stabilizing but still uncertain. Risk disclosures highlight dependence on pharmaceutical and biotechnology R&D budgets, government NIH funding, health care reform, contract termination provisions and international operations, which represent roughly one-half of total net sales.
02—Key points
Key Highlights
- Net sales from continuing operations were $1,142.6 million in 2011, up 0.8% from $1,133.4 million in 2010, with RMS sales up 5.8% and PCS sales down 6.3%.
- Operating income rebounded to $174.3 million from an operating loss of $298.5 million in 2010, which had included a $305.0 million goodwill impairment, $91.4 million of asset impairments and a $30.0 million termination fee.
- Diluted EPS attributable to common shareowners was $2.14 in 2011, versus a diluted loss of $5.38 per share in 2010.
- Gross margin increased to 35.2% of net sales from 33.9%, attributed mainly to cost-savings actions and higher RMS sales.
- The company repurchased 8.4 million shares for approximately $300 million in 2011; $116.3 million remained under the $750.0 million repurchase authorization at year-end.
- PCS backlog was $202.5 million at December 31, 2011, down from $219.9 million at December 25, 2010.
- Cash and cash equivalents fell to $68.9 million from $179.2 million, and total debt was approximately $739 million at December 31, 2011.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Charles River Laboratories International kept $0.10.
- Revenue$1.14B100.0%
- Cost of revenue−$268.0M23.5%
- Gross profit$874.7M76.5%
- Operating costs−$700.4M61.3%
- Operating income$174.3M15.3%
- Interest, other & tax−$64.3M5.6%
- Net income$110.0M9.6%
Where FY2011 revenue went
$1.14B- Other operating costs: $501.7M, 44% of revenue
- Cost of revenue: $268.0M, 23% of revenue
- SG&A: $198.6M, 17% of revenue
- Net income: $110.0M, 9.6% of revenue
- Interest, other & tax: $64.3M, 5.6% of revenue
Kept 9.6% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 27, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $1.14B$1.13B | +0.8% |
| Cost of Revenue | $267.97M$252.96M | +5.9% |
| Gross Profit | $874.68M$880.45M | −0.7% |
| SG&A Expenses | $198.65M$232.49M | −14.6% |
| Operating Income | $174.31M-$298.51M | +158.4% |
| Interest Expense | $42.59M$35.28M | +20.7% |
| Net Income | $109.98M-$336.67M | +132.7% |
| EPS (Basic) | $2.16$-5.38 | +140.1% |
| EPS (Diluted) | $2.14$-5.38 | +139.8% |
| Shares Outstanding (Basic) | 50.82M62.56M | −18.8% |
| Shares Outstanding (Diluted) | 51.32M62.56M | −18.0% |
05—Questions
Frequently Asked Questions
What drove the change from the 2010 operating loss to 2011 operating income?
The 2010 results included a $305.0 million goodwill impairment, $91.4 million of asset impairments and a $30.0 million termination fee tied to a proposed acquisition. None of these charges recurred in 2011, when operating income was $174.3 million. Cost-savings actions also lowered selling, general and administrative expenses to $198.6 million from $232.5 million.
How did the two business segments perform in 2011?
RMS net sales rose 5.8% to $705.4 million, with operating margin of 29.2% versus 27.7% in 2010. PCS net sales fell 6.3% to $437.2 million, and its operating margin was 5.7% compared with negative 81.4% in 2010, which had been affected by impairments.
How much debt does the company carry and what are its main obligations?
Total debt was approximately $739 million at December 31, 2011. This includes $349,995 thousand of 2.25% convertible senior notes due in 2013 and term and revolving loans under a credit agreement maturing in September 2016. The company stated it was compliant with all financial covenants at year-end.
Did the company return capital to shareholders in 2011?
Yes. The company repurchased 8.4 million shares for approximately $300 million during 2011 and reduced weighted average shares outstanding to 51.3 million from 62.6 million. It has not paid cash dividends in the past two years and does not intend to pay them in the foreseeable future.
What risks does the filing highlight for investors?
The filing cites possible declines in preclinical outsourcing, reductions in pharmaceutical and biotechnology R&D budgets, reductions or delays in government (NIH) funding, health care reform, and client contracts that can be terminated on little or no notice. International operations, which represent about one-half of total net sales, add currency and regulatory exposure.
06—Continue